Published in Food and Drug Law Weekly, August 25th, 2006
Rh-Apo2L was approved for clinical trials in May 2005 by China's State Food and Drug Administration (SFDA). The trials were conducted from September 2005 through May 2006 at the Chinese Academy of Medical Sciences Oncology Hospital in Beijing, China.
The phase I clinical trials included 20 patients with advanced-stage malignant tumors. The researched cancer types included non-Hodgkin lymphoma, sarcoma, adrenal gland cortical tumors, non-small...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Food and Drug Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.